PRISM (Psychiatric Ratings using Intermediate Stratified Markers) is a European-wide collaboration between 22 academic and industrial partners. By developing quantitative biological measures for social and cognitive deficits in Alzheimer’s disease, schizophrenia and depression, the PRISM project aims to deepen our understanding of the underlying causes of neuropsychiatric diseases, and to accelerate the discovery and development of better treatments for patients. The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.